Mannkind MNKD Insulin — Purchase Obligation
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mannkind in its filing.
Tagged under the XBRL concept us-gaap:PurchaseObligation.
The official record: Mannkind’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mannkind's insulin — purchase obligation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mannkind's insulin — purchase obligation?
- Mannkind (MNKD) reported insulin — purchase obligation of $64.6M in Q1 2026.
- How has Mannkind's insulin — purchase obligation changed year-over-year?
- Mannkind's insulin — purchase obligation increased by 6.4% year-over-year, from $60.7M to $64.6M.
- What is the long-term trend for Mannkind's insulin — purchase obligation?
- Over 3 years (2021 to 2025), Mannkind's insulin — purchase obligation has grown at a -9.2% compound annual growth rate (CAGR), from $345.9M to $258.8M.
- What does insulin — purchase obligation mean?
- This metric represents the total future financial commitments the company is contractually obligated to pay for goods or services related to the insulin product line. It reflects the long-term liability associated with supply chain agreements and manufacturing capacity requirements. Investors use this to assess the company's fixed cost structure and potential liquidity pressure arising from non-cancellable supply contracts.